Appointments, Earnings Releases, Conference Schedules, and CDIs Delistings - Analyst Notes on DIRECTV, CVS Caremark, McKesson, 21st Century Fox and Cardinal

Tue May 6, 2014 8:14am EDT

* Reuters is not responsible for the content in this press release.

Appointments, Earnings Releases, Conference Schedules, and CDIs Delistings - Analyst Notes on DIRECTV, CVS Caremark, McKesson, 21st Century Fox and Cardinal

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, May 6, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding DIRECTV, Inc. (NASDAQ: DTV), CVS Caremark Corporation (NYSE: CVS), McKesson Corporation (NYSE: MCK), Twenty-First Century Fox, Inc. (NASDAQ: FOXA) and Cardinal Health, Inc. (NYSE: CAH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at:

DIRECTV, Inc. Analyst Notes
On April 30, 2014, DIRECTV, Inc. (DIRECTV) announced the appointment of Jennifer Cho as the Company's Senior Vice President and Treasurer. Jennifer Cho will report to Pat Doyle, Company's Executive Vice President and CFO. In her new role, Cho will lead all aspects of the Treasury and Business Development functions to drive value creation across the Company. Further, she will be responsible for capital structure planning, business development, corporate financings, banking relationships, rating agency relationships, cash management and other aspects of risk management. Commenting on Cho's appointment, Doyle said "Jennifer's more than 25 years of finance experience in areas ranging from credit and risk management to mergers and acquisitions makes her an excellent addition to DIRECTV and the treasury team." The full analyst notes on DIRECTV are available to download free of charge at:

CVS Caremark Corporation Analyst Notes
On May 2, 2014, CVS Caremark Corporation (CVS Caremark) announced its operating results for Q1 2014. During the quarter, the Company reported an increase of 6.3% YoY in its net revenues to $32.7 billion. Pharmacy Services Segment revenues rose 10.3% YoY to $20.2 billion, helped by growth in its specialty pharmacy business, including the acquisition of Coram, as well as drug cost inflation, new clients and new products. Net income for Q1 2014 increased to $1.1 billion, or $0.95 per diluted share, from $954 million, or $0.77 per diluted share in Q1 2013. Net income was positively impacted by rebate improvement in the Pharmacy Services Segment and an increase in front store gross margins in the Retail Pharmacy Segment. The adjusted diluted EPS during Q1 2014 was $1.02, which missed the Reuters' analyst consensus EPS estimate of $1.04. CVS Caremark expects to report adjusted EPS between $1.08 and $1.11 in Q2 2014. The full analyst notes on CVS Caremark are available to download free of charge at:

McKesson Corporation Analyst Notes
On April 29, 2014, McKesson Corporation (McKesson) announced that the Company will participate at the UBS Global Healthcare Conference to be held in New York on Tuesday, May 20, 2014. The Company informed that James Beer, McKesson's Executive Vice President and CFO, will present at the Conference at 12:00 p.m. ET. A live webcast of the conference, and an archived version of the same, will be available for access on the Company's website. The full analyst notes on McKesson are available to download free of charge at:

Twenty-First Century Fox, Inc. Analyst Notes
On May 1, 2014, Twenty-First Century Fox, Inc. (21st Century Fox) announced that trading of its CHESS Depositary Interests (CDIs) on the Australian Securities Exchange (ASX) has been suspended following the Company's previously announced process of delisting from the ASX. The Company is expected to be removed from the official list of the ASX at the close of trading on May 8, 2014 Sydney, Australia time (the Delisting Date). Post the Delisting Date, all of 21st Century Fox's Class A and Class B Common Stock will be listed solely on NASDAQ. Further, as previously stated by the Company, there will be no changes to the Company's operations, employees or business as a result of the delisting from ASX. The full analyst notes on 21st Century Fox are available to download free of charge at:

Cardinal Health, Inc. Analyst Notes
On May 1, 2014, Cardinal Health, Inc. (Cardinal) reported its financial results for Q3 FY 2014 (period ended March 31, 2014). The Company posted 12.7% YoY decline in Q3 FY 2014 net sales to $21.4 billion, weighed down mainly by the Pharmaceutical segment. Revenues from the Pharmaceutical segment declined 14.9% YoY to $18.8 billion as a result of the impact of the expiration of the Walgreens contract. Net earnings for Q3 FY 2014 came in at $315 million, or $0.91 per diluted share, as compared to $345 million, or $1.00 per diluted share in Q3 FY 2013. The decline in earnings reflects the continuing impact of the previously announced Walgreens contract expiration. Further, the company reaffirmed its FY 14 guidance for non-GAAP diluted EPS from continuing operations of $3.75 to $3.85. The full analyst notes on Cardinal are available to download free of charge at:

About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.


1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at]

5. For any urgent concerns or inquiries, please contact us at compliance [at]

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] for consideration.

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.